BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy communication. Krystal Biotech Inc. (NASDAQ:KRYS) said...
BioCentury | Feb 20, 2020
Emerging Company Profile

C. Light opens retinal window to neurological disease

...in Alzheimer’s disease. In a paper published this month in Multiple Sclerosis Journal , the company founders...
BioCentury | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BioCentury | Jan 4, 2020
Emerging Company Profile

Rheos: applying immune cell reprogramming to autoimmunity

...Ventures in 2018 with a $60 million series A round and a platform developed by company founders...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BioCentury | Oct 3, 2019
Politics & Policy

India, African countries will be first to benefit from Biocon’s cheaper insulin plan

Biocon will start making good on its promise of dime a day insulin for developing countries first in India and Africa, company founder Kiran Mazumdar-Shaw told BioCentury. Expanding the availability of low-cost insulin to other...
BioCentury | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....
BioCentury | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

Juvenescence closes $100M series B Juvenescence Ltd. (Douglas, Isle of Man) said it has closed its $100 million series B round and reiterated plans to seek an IPO. Investors included the company's founders plus Grok...
BioCentury | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sunil Verma will become VP, head of breast cancer strategy and global clinical leader in R&D oncology. Verma was head of the department of oncology at University of Calgary and...
Items per page:
1 - 10 of 159
BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy communication. Krystal Biotech Inc. (NASDAQ:KRYS) said...
BioCentury | Feb 20, 2020
Emerging Company Profile

C. Light opens retinal window to neurological disease

...in Alzheimer’s disease. In a paper published this month in Multiple Sclerosis Journal , the company founders...
BioCentury | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BioCentury | Jan 4, 2020
Emerging Company Profile

Rheos: applying immune cell reprogramming to autoimmunity

...Ventures in 2018 with a $60 million series A round and a platform developed by company founders...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BioCentury | Oct 3, 2019
Politics & Policy

India, African countries will be first to benefit from Biocon’s cheaper insulin plan

Biocon will start making good on its promise of dime a day insulin for developing countries first in India and Africa, company founder Kiran Mazumdar-Shaw told BioCentury. Expanding the availability of low-cost insulin to other...
BioCentury | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....
BioCentury | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

Juvenescence closes $100M series B Juvenescence Ltd. (Douglas, Isle of Man) said it has closed its $100 million series B round and reiterated plans to seek an IPO. Investors included the company's founders plus Grok...
BioCentury | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sunil Verma will become VP, head of breast cancer strategy and global clinical leader in R&D oncology. Verma was head of the department of oncology at University of Calgary and...
Items per page:
1 - 10 of 159